2007至2016年澳大利亚维多利亚州儿童免疫接种后皮下结节分析
基于澳大利亚SAEFVIC监测系统2007年5月至2016年6月报告的58例18岁以下儿童注射部位结节病例,采用Brighton合作组病例定义进行评估。71%(41/58)符合皮下结节定义,中位免疫接种年龄12个月,多数结节在接种后3天内出现且位于大腿,约四分之一持续超过24个月。结论认为皮下结节可发生于多种疫苗(包括不含铝疫苗)接种后,需仔细评估并尽可能由专科管理以支持后续免疫接种。
要点
- 71%(41/58)报告病例符合Brighton合作组皮下结节病例定义。
- 结节多与含铝疫苗相关(74%,36/49个结节),但8%(4个结节)与不含铝疫苗相关。
- 34%的结节在免疫后6个月消退,68%在12个月消退,24%持续超过24个月。
核心结论
- 注射部位皮下结节可发生于多种疫苗接种后,包括不含铝的疫苗。
- 所有病例均需仔细评估,并尽可能由专科管理以支持后续免疫接种。
研究设计与样本
- 对2007年5月至2016年6月期间报告至澳大利亚墨尔本SAEFVIC的58例18岁以下「注射部位结节」病例进行回顾性分析。
- 通过记录和电话随访获取病例详情,并查阅澳大利亚免疫登记册了解免疫接种状态。
主要发现
- 71%(41/58)报告病例符合Brighton合作组皮下结节定义,14%(8例)为「可能皮下结节」,10%(6例)为卡介苗接种相关结节,5%(3例)归因于其他诊断。
- 免疫接种时中位年龄为12个月(范围1个月至12岁),54%(22/41例)为男性,17%(7例)有多个结节。
- 结节与含铝疫苗相关占74%(36/49个结节),不含铝疫苗占8%(4个结节),未知占18%(9个结节)。
- 大多数病例在免疫接种后3天内出现症状(59%,24例),结节位于大腿占59%(29个结节),41%(17例)伴有瘙痒。
- 约三分之一(34%)的结节在免疫接种后6个月消退,三分之二(68%)在12个月消退,但四分之一(24%)持续超过24个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Subcutaneous nodules are a rare adverse event following immunization (AEFI). We aimed to describe nodules at the injection site reported to SAEFVIC (Surveillance of Adverse Events Following Vaccination in the Community) using the Brighton Collaboration Case Definition (BCCD), management and recurrence following subsequent immunizations. METHOD: We assessed 58 cases (<18 years of age) of 'nodule at injection site' reported to SAEFVIC, Melbourne, Australia, between May 2007 and June 2016. Case details were analyzed from records and phone interview follow-up. The Australian Immunization Registry was reviewed for immunization status. RESULTS: 71% (41/58 reported cases) were consistent with the BCCD for subcutaneous nodule, 14% (8 cases) were 'possible subcutaneous nodules', 10% (6 cases) were nodules associated with BCG immunization and 5% (3 cases) were attributable to an alternative diagnosis. The median age at immunization was 12 months, (range 1 month-12 years); 54% male (22/41 cases). 17% (7 cases) had multiple nodules. Nodules were associated with immunizations containing aluminum (74%, 36/49 nodules), no aluminum (8%, 4 nodules) and unknown (18%, 9 nodules). Most cases developed symptoms within 3 days post-immunization (59%, 24 cases) and in the thigh (59%, 29 nodules). Pruritus was associated in 41% (17 cases). Around 1/3 (34%) of nodules resolved 6 months post immunization, 2/3 (68%) by 12 months, however 1/4 (24%) remained persistent for >24 months. 5 cases had prior nodules and 1 case had recurrence with subsequent immunization. 83% (34 cases) were fully immunized for age at follow-up. CONCLUSION: Subcutaneous nodules at the injection site may occur following a wide range of vaccines, including vaccines without aluminum. All cases require careful review and where possible, specialist management and to support subsequent immunizations.
引用
- Silcock R, Crawford NW, Selvaraj G, et al. Subcutaneous nodules following immunization in children; in Victoria, Australia from 2007 to 2016. Vaccine. 2020. PMID: 32147295. doi:10.1016/j.vaccine.2019.12.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。